Clinical trial
Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK…
NCT00359983 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00359983 |
|---|---|
| Title | Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB |
| Official title | A Study to Evaluate the Long-term Antibody Persistence at 1, 3 & 5 Years After the Administration of a Fourth Dose of Hib-MenCY-TT Vaccine Compared to ActHIB in Subjects Boosted in a Previous Study. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neisseria Meningitidis, Haemophilus Influenzae Type b |
| Intervention type | Biological |
| Interventions | MenHibrix (Hib-MenCY-TT), Hib conjugate vaccine (ActHIB) |
| Enrollment | 270 |
| Start date | Sep 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | May 1, 2011 |
| First posted | Aug 3, 2006 |
| Last update posted | Dec 16, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: